A Phase II Trial of Alisertib ( MLN8237 ) in Salvage Malignant Mesothelioma
نویسندگان
چکیده
منابع مشابه
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
BACKGROUND To assess the response rate, toxicity and survival in patients with malignant pleural mesothelioma treated with liposomal daunorubicin. The study design allowed for dose escalation pending toxicity. PATIENTS AND METHODS Liposomal daunorubicin (DaunoXome, Nexstar, USA) 120 mg/m2 was administered every 21 days to a maximum of 6 cycles. Patients had to have histologically-proven malig...
متن کاملTrimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less). Induction chemotherapy consisted of three courses...
متن کاملPRIMARY MALIGNANT PERICARDIAL MESOTHELIOMA
Primary malignant neoplasms of the pericardium are rare and are predominantly mesotheliomas, followed by benign localized fibrous mesothelioma, malignant fibrosarcoma, angiosarcoma and benign and malignant teratomas. 1 This article concerns an atypical presentation of this malignant tumor with symptoms and signs of pericardial effusion. This unusual feature was complete encasement of the h...
متن کاملAn exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete...
متن کاملThoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months. Although multimodality protocols that combine aggressive surgery and adjuvant chemotherapy or radiotherapy have shown improved survival in selected cases, the majority of patients with MPM are not suitable for radical surgery due to advanced stage and comorbid medi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2020
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2020-0610